Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 05/24/19

Clinical Investigations Branch (CIB)

The Clinical Investigations Branch (CIB) is responsible for:

  • Scientific coordination and oversight of the NCI’s National Clinical Trials Network Program (NCTN)
  • Organization of comprehensive programs of preliminary and definitive clinical trials of precision medicine, such as Lung-MAP, ALCHEMIST, NCI-MATCH, and a pediatric version of NCI- MATCH
  • Organization of innovative treatment, single/multiple agent or combined modalities, for adult, adolescent, and pediatric populations
  • Facilitation and organization of clinical research including surgical and radiation therapy, as well as chemo-, biologic- and immuno-therapies in the treatment of cancer
  • Coordination with the extramural scientific community and other NCI programs, such as the Coordinating Center for Clinical Trials (CCCT), on identifying and prioritizing trials for disease-related research
  • Coordination with other NCI programs regarding collection, banking, and use of clinical biospecimens in conjunction with validated data from clinical trials
  • Collaboration with NCTN groups, consortia, cancer centers and other entities in the development/harmonization of research standards and methodologies
  • Collaboration with international clinical trials organizations
  • Oversight of pediatric drug development, from testing of novel agents through the Pediatric Preclinical Testing Consortium (PPTC) to clinical evaluations of novel agents by CIB-supported pediatric clinical trials organizations
  • Coordination and oversight of the adult and pediatric brain tumor consortia
  • Collaboration with the NCI Central Institutional Review Board (CIRB), which with one centralized review, enables investigators to enroll patients into NCTN trials significantly faster than when obtaining approval from a local IRB
  • Cooperation with the Cancer Trials Support Unit (CTSU), which simplifies admittance to NCTN trials for qualified clinical sites and supports the conduct of those clinical trials

About the Branch Chief

Meg Mooney, MD Meg Mooney, MD, MBA, became the Acting Associate Director of CTEP in December 2018, with oversight and coordination responsibilities for the programmatic, financial, and administrative functions for the entire CTEP program, which covers a broad, multidisciplinary, clinical research effort to coordinate nationwide phase 1-3 clinical trials programs testing new treatment approaches for cancer. She is also the Chief of the Clinical Investigations Branch. More…